Phendimetrazine
Pharmaceutical drug
From Wikipedia, the free encyclopedia
Phendimetrazine, sold under the brand name Bontril among others, is a stimulant medication of the morpholine chemical class used as an appetite suppressant.[2]
| |
 | |
| Clinical data | |
|---|---|
| Trade names | Bontril |
| Other names | Mephenmetrazine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine |
| AHFS/Drugs.com | Monograph |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Liver |
| Elimination half-life | 19–24 hours |
| Excretion | Urinary elimination |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.010.186 |
| Chemical and physical data | |
| Formula | C12H17NO |
| Molar mass | 191.274 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pharmacology
Phendimetrazine functions as a prodrug of phenmetrazine; approximately 30% of an oral dose is converted into it. Phendimetrazine can essentially be thought of as an extended-release formulation of phenmetrazine with less potential for abuse. Phendimetrazine is an anorectic drug which acts as a norepinephrine–dopamine releasing agent (NDRA).[3]
As an amphetamine congener, its structure incorporates the backbone of methamphetamine, a potent CNS stimulant. While the addition of an N-methyl group to amphetamine significantly increases its potency and bioavailability, methylation of phenmetrazine renders the compound virtually inactive. However, phendimetrazine is a prodrug for phenmetrazine which acts as the active metabolite. Phendimetrazine possesses preferable pharmacokinetics over phenmetrazine as a therapeutic agent because its metabolization by demethylases produces a more steady and prolonged exposure of active drug within the body.[4] This decreases abuse potential as the peak blood-concentration of active phenmetrazine that's produced from a single dose of phendimetrazine is lower than a single therapeutically equivalent dose of phenmetrazine.
Indicated as a short-term secondary treatment for exogenous obesity, phendimetrazine immediate-release 35 mg tablets are typically consumed one hour before meals, not to exceed three doses daily. Phendimetrazine is also manufactured as a 105 mg extended-release capsule for once daily dosing, typically consumed 30 to 60 minutes before a morning meal. Whereas the immediate-release formulation has a maximum daily dosage of 210 mg (6 tablets), the extended-release capsules have a maximum daily dosage of 105 mg (one capsule).[citation needed]
Legality
According to the List of Psychotropic Substances under International Control published by the International Narcotics Control Board, phendimetrazine is a Schedule III controlled substance under the Convention on Psychotropic Substances.[5]
Synthesis
The reaction between 2-bromopropiophenone 1 and N-methylethanolamine 2 produces the intermediate of 3a/b in equilibrium, which is reductively cyclized using formic acid to yield phendimetrazine.
